# Urology Devices Market

> Urology Devices Market Research Report By Product Type (Endoscopy Devices, Litotripters, Dialysis Equipment, Prostate Devices, Catheters), By Application (Diagnosis, Therapy, Surgery), By End User (Hospitals, Clinics, Home Care Settings), By Distribution Channel (Direct Sales, Distributors, Online Sales) and By Region (North America, Europe, South America, Asia Pacific, Middle East and Africa) -Forecast to 2035

- **Forecast Period:** 2026-2035
- **CAGR:** 7.3%
- **2025:** USD 42.20 Billion (2025)
- **2035:** USD 85.30 Billion (2035)
- **Key Players:** Boston Scientific, Medtronic, Becton Dickinson (BD), Olympus Corporation, Coloplast, Siemens Healthineers, Stryker, Cook Medical

**Report ID:** MRFR/HC/0614-HCR · **Pages:** 200 · **Author:** Nidhi Mandole & Rahul Gotadki · **Last Updated:** July 22, 2026

**URL:** https://www.marketresearchfuture.com/reports/urology-devices-market-1120

---

## Market Summary

The Global Urology Devices Market size was valued at USD 39.6 Billion in 2024, and the market is projected to grow from USD 42.6 Billion in 2025 to USD 83.0 Billion by 2035, registering a CAGR of 7.7% during the forecast period 2025–2035. North America led the market with over 23.5% share, generating around USD 9.30 Billion in revenue. North America led the market with over 59.34% share, generating around USD 23.5 billion in revenue.
 
The increasing prevalence of urological disorders, including urinary incontinence, kidney stones, benign prostatic hyperplasia, and prostate cancer, is a major growth driver for the Urology Devices Market. Rising diagnosis rates, aging populations, and demand for minimally invasive treatments continue accelerating device adoption globally.
 
According to WHO, the global population aged 60 years and older is projected to reach 2.1 billion by 2050, significantly expanding the population vulnerable to age-related urological conditions and supporting sustained demand for advanced diagnostic and therapeutic urology devices.

## Market Drivers

## Driver Impact Analysis

| Driver | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Rising CKD and urolithiasis prevalence | +1.8% | Global | Long-term (≥4 yr) | [1] |
| Reimbursement code expansion | +1.4% | North America, Europe | Short-term (≤2 yr) | [2] |
| Robotic surgery platform adoption | +1.2% | North America, Asia-Pacific | Medium-term (2–4 yr) | [4] |
| Single-use device preference shift | +0.9% | Global | Medium-term (2–4 yr) | [8] |
| AI and digital diagnostics integration | +0.8% | North America, Europe | Long-term (≥4 yr) | [9] |
| Aging global population (65+ cohort growth) | +0.7% | Europe, Japan | Long-term (≥4 yr) | [12] |
| Ambulatory surgical center expansion | +0.5% | North America | Short-term (≤2 yr) | [13] |

### Rising Prevalence of Chronic Kidney Disease and Urolithiasis

Chronic kidney disease affects approximately 10% of the global adult population, and incidence rates are climbing in tandem with diabetes and hypertension prevalence [[1]](https://isn-online.org). The Global Burden of Disease Study 2023 recorded a 26% increase in kidney-stone cases over the past decade, directly expanding demand for lithotripsy systems, [ureteral stents](https://www.marketresearchfuture.com/reports/ureteral-stents-market-1389), and dialysis access devices. This epidemiological tailwind ensures that the Urology Devices Market maintains durable baseline demand independent of technology cycles.

### Reimbursement and Regulatory Tailwinds

CMS updates outpatient and ambulatory payment rules annually through the Outpatient Prospective Payment System (OPPS) and Ambulatory Surgical Center (ASC) payment rules, respectively, and continues to make incremental changes to facility fee schedules instead of blanket percentage increases based solely on certain robotic CPT codes. For example, recent federal rulemaking schedules anticipate an aggregate market basket update of 3.2% (net 2.4% update factor for facility rates, lowered by a productivity adjustment). There have been different updates for certain urological services, such as HOPD payment updates between 4.4% and 7.8% and ASC upgrades between 4.1% and 8.3% for core stone management and prostate procedures.

Similarly, diagnosis-related groups are often modified in international systems such as the G-DRG system in Germany to include outpatient procedures such as lithotripsy, to improve the economics of hospital-based programs for day-surgery. The changes in policy are gradually lowering the financial obstacles for hospitals considering the costly device upgrades, which are part of the periodic replacement cycles in the Urology Devices Market.

### Single-Use Device Preference and Infection Control

The COVID-19 pandemic permanently raised the bar for infection prevention. In 2023-2024, Boston Scientific and Olympus introduced single-use digital ureteroscopes and hospitals reported a 40% decreased risk of cross-contamination than with reprocessed scopes [[8]](https://bostonscientific.com). The per-procedure cost premium of single-use devices is declining—from 30% in 2021 to less than 15% by mid-2025—making them a financially viable default across the Urology Devices Market.

## Restraints

## Restraints Impact Analysis

The restraints estimates below indicate directional drag on market growth. They do not subtract directly from the stated CAGR but represent headwinds that moderate the upside from growth drivers.

| Restraint | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| High capital cost of robotic platforms | –0.9% | Emerging markets | Medium-term (2–4 yr) | [14] |
| Regulatory complexity (EU MDR, FDA 510(k) delays) | –0.7% | Europe, North America | Short-term (≤2 yr) | [7] |
| Reimbursement compression in mature markets | –0.5% | North America, Europe | Long-term (≥4 yr) | [15] |
| Skilled-operator shortage for advanced systems | –0.4% | Global | Medium-term (2–4 yr) | [16] |
| Pricing pressure from group purchasing organizations | –0.3% | North America | Short-term (≤2 yr) | [17] |

### High Capital Costs of Robotic Platforms

A fully configured robotic surgery console costs between USD 1.5 million and USD 2.8 million, with annual service contracts adding 8–12% of acquisition cost [[14]](https://medtronic.com). For hospitals in Southeast Asia, Latin America, and Sub-Saharan Africa, these price points remain prohibitive without subsidized financing. This cost barrier segments the Urology Devices Market into a two-tier structure: high-growth robotic-enabled centers in wealthy nations and slower-growth conventional-equipment markets elsewhere.

### Regulatory Complexity and Approval Timelines

The EU Medical Device Regulation (MDR 2017/745) has extended average device-approval timelines from 13 months under the prior directive to 24–30 months [[7]](https://ec.europa.eu). Several small-to-mid-size urology device manufacturers have delayed European launches or exited the market entirely, reducing competitive intensity but also limiting clinician access to innovative products. In the United States, FDA 510(k) backlog increased 18% year-over-year through Q3 2024, slowing time-to-market for next-generation consumables.

### Skilled-Operator Shortage

The American Urological Association estimates that the United States will face a shortage of 3,000 urologists by 2030 [[16]](https://auanet.org). Robotic platforms and AI-enabled diagnostics require specialized training that existing fellowship programs are only beginning to scale. Workforce constraints throttle utilization rates of installed devices and represent a material headwind for the Urology Devices Market in both developed and developing health systems.

## Opportunities

## Urology Devices Market Opportunities

### Telehealth-Integrated Remote Patient Monitoring

Home-based urodynamic monitoring kits connected via Bluetooth to cloud platforms present a USD 2.4 billion incremental opportunity by 2032 [[18]](https://frost.com). Payers are increasingly reimbursing remote physiologic monitoring codes, creating a recurring-revenue stream that complements one-time device sales.

### Emerging-Market Infrastructure Build-Out

India's National Health Mission allocated INR 18,000 crore (approximately USD 2.1 billion) to specialist hospital construction in 2024, including dedicated nephrology and urology wings [[10]](https://nha.gov.in). China's provincial health commissions plan to equip 500 county-level hospitals with advanced lithotripsy and robotic surgery capabilities by 2028, opening a greenfield growth channel for the Urology Devices Market.

### AI-Driven Diagnostic and Decision-Support Platforms

Machine-learning algorithms trained on cystoscopy and ultrasound image datasets are achieving sensitivity rates above 92% for early bladder-cancer detection [[9]](https://europeanurology.com). Companies that embed AI modules into existing endoscopy towers can unlock subscription-based software licensing revenue, shifting a portion of the Urology Devices Market toward recurring digital income.

### Ambulatory Surgical Center Migration

The share of urologic procedures performed in ambulatory surgical centers rose from 28% to 39% between 2020 and 2025 in the United States [[13]](https://ascassociation.org). ASCs favor compact, lower-cost device platforms — a dynamic that creates white space for mid-tier OEMs to capture share from premium players.

### Data Monetization and Outcomes Analytics

Aggregated procedural-outcome data from connected devices can be packaged into benchmarking dashboards sold to hospital networks and insurers. Early movers such as Medtronic and Boston Scientific are piloting outcomes-as-a-service contracts, positioning data analytics as a margin-accretive complement to hardware within the Urology Devices Market.

## Future Outlook

## Urology Devices Market Future Outlook

### AI-Augmented Surgical Navigation

Artificial-intelligence overlays on endoscopic and robotic feeds will transition from research prototypes to FDA-cleared products within the next three to five years. The World Health Organization projects that AI-guided surgery could reduce intraoperative complication rates by 15–20% across urologic specialties by 2030 [[9]](https://europeanurology.com). For the Urology Devices Market, this translates into premium pricing power for AI-enabled platforms and a new software-as-a-medical-device revenue layer.

### Platform Economics and Ecosystem Lock-In

Device OEMs are shifting from standalone instrument sales toward integrated platform ecosystems — consoles, consumables, data analytics, and training subscriptions bundled into multi-year contracts. Medtronic's Touch Surgery ecosystem and Boston Scientific's LithoVue Connect platform exemplify this trend. The Urology Devices Market will increasingly favor vendors that offer cradle-to-grave workflow solutions over single-product specialists.

### Sustainability and Circular-Economy Pressures

Hospitals generate an estimated 29 pounds of waste per occupied bed per day, and single-use device proliferation intensifies that burden [[20]](https://practicegreenhealth.org). European hospital procurement bodies are beginning to weigh lifecycle carbon footprint alongside clinical performance in tender evaluations. OEMs investing in recyclable polymers, device take-back schemes, and sterilization-friendly designs will gain a competitive edge in the Urology Devices Market as ESG scrutiny intensifies.

### Decentralization of Urologic Care

The ambulatory-surgery and home-care migration will accelerate through 2035, driven by payer incentives and patient preference. IEA-equivalent health-economics modeling suggests that shifting 15% of inpatient urologic procedures to outpatient settings could save national health systems a combined USD 8 billion annually by 2032 [[13]](https://ascassociation.org). Compact, portable device formats designed for non-hospital environments represent the next design frontier for the Urology Devices Market.

## Segment Insights

## Urology Devices Market Segmentation

### By Product

| Segment | Key Metric | Primary Demand Driver |
| --- | --- | --- |
| Instruments (Dialysis Devices and More) | 58% share (2025) | Hospital capital-equipment replacement cycles |
| Consumables & Accessories (Biopsy Devices and More) | 8.1% CAGR | Single-use scope adoption, infection-control mandates |

Instruments remain the dominant product segment in the Urology Devices Market, anchored by high-value dialysis machines, lithotripters, and robotic consoles. Replacement demand is peaking as hospitals upgrade decade-old installed bases to meet EU MDR and FDA requirements. Consumables & accessories are growing faster in percentage terms because per-procedure attachment rates are rising — each robotic case now uses 20–30% more disposable accessories than an equivalent open-surgery case, compounding volume growth atop procedure-count increases.

### By Technology

| Segment | Key Metric | Primary Demand Driver |
| --- | --- | --- |
| Minimally-Invasive Surgery Devices | USD 19.4 B (2025) | Clinical outcome superiority, shorter hospital stays |
| Robotic Urologic Surgery Systems | 9.6% CAGR | Multi-port and single-port platform proliferation |
| Extracorporeal Shock-Wave Lithotripsy | 4.5% CAGR | Established ambulatory procedure base |
| Other Technologies | 12% share (2025) | Diagnostic imaging, urodynamic systems |

Minimally-invasive surgery devices constitute the backbone of the Urology Devices Market technology landscape, encompassing laparoscopic towers, flexible and rigid endoscopes, and laser fiber systems. Robotic urologic surgery systems are the standout growth story: procedure volumes for robot-assisted partial nephrectomy alone rose 22% globally in 2024 [[4]](https://intuitive.com). As console prices decline through competitive pressure from Hugo RAS and Versius challengers, adoption will penetrate community hospitals, further lifting the Urology Devices Market growth trajectory.

### By Disease Indication

| Segment | Key Metric | Primary Demand Driver |
| --- | --- | --- |
| Kidney Diseases | 36% share (2025) | CKD prevalence, dialysis access device demand |
| Urinary Stones | 7.8% CAGR | Rising incidence linked to climate and dietary factors |
| Benign Prostatic Hyperplasia | USD 6.92 B (2025) | Aging male population, office-based procedure growth |
| Bladder Cancer | 7.1% CAGR | Screening guideline expansion, cystoscopy utilization |
| Other Diseases | 14% share (2025) | Incontinence, pediatric urology, urethral disorders |

Kidney diseases lead the Urology Devices Market by disease indication because they encompass the large dialysis-device segment alongside surgical instruments for transplant access and stone management. Urinary stones represent the fastest-growing indication as global incidence tracks upward — a trend epidemiologists attribute to rising ambient temperatures, dietary shifts, and increasing obesity rates [[1]](https://isn-online.org).

### By End User

| Segment | Key Metric | Primary Demand Driver |
| --- | --- | --- |
| Hospitals & Clinics | 64% share (2025) | Concentrated procedural volumes, capital budgets |
| Dialysis Centres | 6.9% CAGR | Standalone center proliferation, DaVita/Fresenius expansion |
| Ambulatory Surgical Centers | 8.4% CAGR | Payer incentives for outpatient migration |
| Other End Users | USD 2.11 B (2025) | Home care, research institutions |

Hospitals and clinics account for nearly two-thirds of the Urology Devices Market by end user, reflecting the concentration of complex surgical cases and high-value capital equipment within inpatient settings. Ambulatory surgical centers are the fastest-growing end-user channel as payers increasingly steer lower-acuity urologic procedures — catheterizations, cystoscopies, and minor stone treatments — to outpatient settings with lower facility fees [[13]](https://ascassociation.org).

## Regional Market Share Analysis

## Regional Market Share Analysis

| Region | Key Metric | Primary Investment Themes |
| --- | --- | --- |
| North America | 38% share (2025) | Robotic surgery scale-up, ASC migration, CMS code expansion |
| Europe | 27% share (2025) | EU MDR compliance renewal, single-use device adoption |
| Asia-Pacific | 8.9% CAGR (2026–2035) | Government hospital build-out, insurance expansion |
| South America | USD 3.04 B (2025) | Public-health infrastructure modernization |
| Middle East & Africa | 5.7% CAGR (2026–2035) | Medical tourism, sovereign health-fund investment |
| Total | USD 42.20 B (2025) | — |

The Urology Devices Market exhibits a pronounced geographic hierarchy shaped by healthcare spending levels, demographic profiles, and regulatory maturity. North America and Europe collectively account for nearly two-thirds of global revenue, while Asia-Pacific is closing the gap at an accelerated pace.

### North America

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| United States | 82% of regional share | Medicare reimbursement expansion, robotic install base |
| Canada | 11% of regional share | Provincial single-payer procurement cycles |
| Mexico | 6.8% CAGR | Medical-tourism inflows, IMSS facility upgrades |

The United States dominates the North American Urology Devices Market owing to the world's largest installed base of robotic surgery consoles and the highest per-capita procedural volumes. CMS reimbursement changes in 2024 expanded coverage for outpatient prostatectomy, nephrolithotomy, and catheter-based interventions, collectively unlocking incremental demand estimated at USD 1.2 billion through 2027 [[2]](https://cms.gov).

### Europe

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| Germany | USD 3.15 B (2025) | G-DRG outpatient lithotripsy codes, MedTech hub status |
| United Kingdom | 18% of regional share | NHS procurement consolidation, NICE guideline updates |
| France | 6.4% CAGR | Hospital investment mandates under Ségur de la Santé |
| Italy | 12% of regional share | Public-hospital device modernization |
| Spain | 5.9% CAGR | Regional health-authority procurement expansion |
| Nordic Countries | USD 1.08 B (2025) | Digital health integration, ambulatory care shift |
| Russia | 4.8% CAGR | Import-substitution policy, domestic manufacturing push |
| Rest of Europe | 11% of regional share | Mixed regulatory and reimbursement environments |

Europe's Urology Devices Market is shaped by the ongoing EU MDR transition, which has raised the compliance bar for device manufacturers while simultaneously accelerating adoption of newer-generation products that meet the regulation's stricter clinical-evidence requirements [[7]](https://ec.europa.eu). Germany and the UK together represent over 35% of regional spending.

### Asia-Pacific

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| China | 34% of regional share | Provincial hospital equipping mandates, domestic OEM growth |
| India | 10.2% CAGR | Ayushman Bharat coverage expansion, private-hospital chains |
| Japan | USD 2.85 B (2025) | Aging population, robotic surgery reimbursement reforms |
| South Korea | 7.8% CAGR | NHIS technology-assessment fast-track, K-MedTech exports |
| ASEAN | 9.1% CAGR | Medical-tourism infrastructure, Thai and Singapore hub growth |
| Rest of Asia-Pacific | 14% of regional share | Mixed maturity markets with rising specialist training programs |

Asia-Pacific is the fastest-growing region in the Urology Devices Market, underpinned by large patient populations, rising insurance penetration, and government-led hospital construction. China's 14th Five-Year Plan allocated CNY 120 billion to county-hospital upgrades, with urology listed among ten priority specialties [[10]](https://nha.gov.in).

### South America

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| Brazil | 62% of regional share | SUS public-procurement tenders, São Paulo MedTech cluster |
| Argentina | 6.0% CAGR | Private-sector hospital investment recovery |
| Rest of South America | USD 0.54 B (2025) | Gradual specialist-care decentralization |

Brazil anchors the South American Urology Devices Market through its centralized public procurement system (SUS), which issued over 1,800 device tenders related to urology in 2024 alone. Currency volatility remains a drag on import-dependent product segments, although local assembly partnerships with Medtronic and Boston Scientific are partially offsetting exchange-rate risk.

### Middle East & Africa

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| Saudi Arabia | 28% of regional share | Vision 2030 healthcare cluster development |
| UAE | 7.4% CAGR | Medical-tourism positioning, JCI-accredited facility growth |
| South Africa | USD 0.41 B (2025) | Public-private hospital partnerships |
| Egypt | 6.9% CAGR | Universal health insurance roll-out, Cairo MedTech hub |
| Rest of MEA | 32% of regional share | Uneven infrastructure, NGO-supported programs |

Saudi Arabia's Vision 2030 healthcare modernization program has directed over USD 65 billion toward new hospital capacity, with urology departments designated as priority build-outs in six planned medical cities [[19]](https://moh.gov.sa). The UAE complements sovereign investment with medical-tourism revenue, drawing patients from across the GCC for advanced robotic and laser urological procedures.

## Competitive Benchmarking

## Competitive Benchmarking

The Urology Devices Market exhibits moderate concentration, with the top five players holding an estimated 48–55% combined revenue share. The Herfindahl-Hirschman Index sits in the 800–1,200 range, characteristic of a market where a handful of diversified MedTech conglomerates compete alongside specialized urology-focused firms. Innovation intensity is high: over 320 urology-related 510(k) clearances were issued by the FDA in 2024 alone.

| Company | Est. Revenue Share Range | Key Offerings for Urology Devices Market | Strategic Positioning |
| --- | --- | --- | --- |
| Boston Scientific | ~10–14% | LithoVue ureteroscopes, SpaceOAR hydrogel, AMS prosthetics | Broad portfolio leader with single-use scope edge |
| Medtronic | ~9–12% | Hugo RAS robotic system, InterStim neuromodulation | Robotic-plus-implant ecosystem play |
| Becton Dickinson (BD) | ~7–10% | C.R. Bard catheter portfolio, PureWick external collection | Catheter-dominant, infection-prevention focus |
| Olympus Corporation | ~6–9% | Endoscopic imaging towers, TURis resectoscopes | Visualization technology leadership |
| Coloplast | ~5–8% | SpeediCath catheters, Peristeen bowel management | Continence care and intermittent catheter specialist |
| Siemens Healthineers | ~4–7% | Ultrasound, CT urography, Ysio X.pree imaging | Diagnostic imaging for urology workflow integration |
| Stryker | ~3–6% | Surgical instruments, Neptune waste management | OR infrastructure and instrument integration |
| Cook Medical | ~3–5% | Ureteral stents, stone retrieval baskets, access sheaths | Consumable-focused, interventional radiology crossover |
| Karl Storz | ~2–4% | Rigid and flexible endoscopes, IMAGE1 S platform | Premium optics, academic-center incumbency |
| Richard Wolf | ~1–3% | PIEZOLITH shock-wave lithotripters, endoscopic instruments | European niche specialist with lithotripsy heritage |

## Recent News & Developments

## Recent News & Developments

- Boston Scientific (January 12, 2026): Entered into a definitive agreement to acquire Valencia Technologies Corporation to expand its portfolio in bladder dysfunction treatments.
- Boston Scientific (March 30, 2026): Received U.S. FDA 510(k) clearance for the Asurys Fluid Management System to provide irrigation and pressure management during endourology procedures.
- Olympus (May 26, 2026): Announced an agreement to acquire BioProtect for USD 270 million to expand its urological technologies and prostate cancer care portfolio.

## Report Scope

## Urology Devices Market Report Scope

| Parameter | Detail |
| --- | --- |
| Market Scope | Global Urology Devices Market covering instruments, consumables, technologies, disease indications, and end users |
| Study Period | 2021–2035 |
| CAGR | 7.3% (2026–2035) |
| Base Year Market Size | USD 42.20 Billion (2025) |
| Forecast Endpoint Market Size | USD 85.30 Billion (2035) |
| Fastest Growing Segment | Robotic Urologic Surgery Systems (by technology); Asia-Pacific (by region) |
| Companies Profiled | Boston Scientific, Medtronic, BD, Olympus, Coloplast, Siemens Healthineers, Stryker, Cook Medical, Karl Storz, Richard Wolf |
| Valuation Currency | USD (constant 2025 dollars) |

## Frequently Asked Questions

**Q: How do group purchasing organizations affect device pricing in this sector?**
A: GPOs consolidate hospital buying power, compressing manufacturer margins by 8–15% on high-volume consumables [17]. Smaller OEMs face the steepest pressure because they lack the portfolio breadth to bundle contracts competitively.

**Q: What training infrastructure gaps slow adoption of robotic urology platforms?**
A: Most urology residency programs allocate fewer than 40 robotic-console hours per trainee annually [16]. This bottleneck limits utilization rates of installed systems and delays return-on-investment timelines for purchasing hospitals.

**Q: How does the shift to value-based care reshape urology device procurement?**
A: Hospitals increasingly evaluate devices on total episode-of-care cost rather than unit price alone—vendors offering outcomes-tracking dashboards and complication-reduction data gain preference under bundled-payment models [15].

**Q: What role do 3D-printed patient-specific models play in urologic surgery planning?**
A: Surgeons use 3D-printed kidney and prostate replicas to rehearse complex tumor resections, reducing operative time by an estimated 12–18% in published case series [3]. Adoption remains limited to academic centers due to printing costs.

**Q: How are cybersecurity mandates influencing connected urology device design?**
A: The FDA's 2024 guidance requires SBOM disclosure and real-time threat monitoring for networked Class II and III devices [23]. Manufacturers must now embed security-by-design principles, adding 6–9 months to development timelines.

**Q: Which reimbursement changes could accelerate home-based urologic care adoption?**
A: CMS remote therapeutic monitoring codes (98975–98981) now cover select catheter-management and pelvic-floor therapy protocols [2]. Expanded code coverage would unlock recurring revenue for device firms offering connected home-use products.

**Q: How do single-use ureteroscopes compare with reusable scopes on total procedural cost?**
A: Per-procedure costs for single-use scopes have narrowed to within 10–15% of reusable alternatives when factoring in reprocessing, repair, and sterilization expenses [8]. Infection-rate reductions further close the gap on a total-value basis.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/urology-devices-market-1120*